Novartis in constant evolution: new large investment in startup

Israel-based Gamida Cell Ltd is ready for Nasdaq IPO. The young biotech has developed novel, nicotinamide-based cell therapies, the most relevant of which is NiCord, for patients with serious hematologic diseases that need hematopoietic stem cell transplant (HSCT).